132 search results for: symposium

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
Dermatology
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
expert video

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).

View more
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
Rhinology
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
expert video

The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

View more
Head-to-Head Trials of Biologics in CRSwNP
Rhinology
Head-to-Head Trials of Biologics in CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.

View more
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
Rhinology
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

View more
ADVENT at WCI
Congress
12
October
2025
Congress
ADVENT at WCI 2025

Join ADVENT for an educational symposium on PN at WCI 2025!

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
Rhinology
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
expert video

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

View more
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
Rhinology
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
expert video

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

View more
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
expert video

Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

View more
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
expert video

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

View more
.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.